Johnson & Johnson's IBD Therapy Fails to Meet Primary Endpoint in Clinical Trial

Johnson & Johnson's JNJ-4804, combining Tremfya and Simponi for inflammatory bowel disease, failed to meet the primary endpoint of clinical remission in Phase 2b trials for ulcerative colitis and Crohn's disease, with results presented May 5, 2026. The DUET study follows a 2022 clinical trial that nearly doubled remission rates and spurred industry-wide combination therapy development. Despite missing statistical significance, the combination performed better than individual drugs.

DUET trial results

• ▪Johnson & Johnson's DUET study is a follow-up to a 2022 clinical trial that showed a significant benefit to patients, nearly doubling the rates of disease remission.
• ▪Trial investigators presented the results of Johnson & Johnson's DUET study on May 5, 2026.
• ▪Johnson & Johnson's DUET study tested how well combining the drugs Tremfya and Simponi would stop the immune system from mistakenly attacking healthy tissues in the digestive tract.

Combination therapy approach

• ▪The 2022 clinical trial showing significant benefit to inflammatory bowel disease patients spurred several companies to start developing combination approaches for IBD.
• ▪Johnson & Johnson's combined therapy for inflammatory bowel disease is dubbed JNJ-4804.

Phase 2b clinical endpoints

• ▪In each Phase 2b trial, Johnson & Johnson's combination therapy performed better than the individual drugs, but did not meet the primary endpoint of clinical remission.
• ▪Johnson & Johnson's therapy for inflammatory bowel disease failed to show a statistically meaningful improvement for patients.
• ▪Johnson & Johnson tested JNJ-4804 in two Phase 2b clinical trials hitting both major forms of inflammatory bowel disease — ulcerative colitis and Crohn's disease.

Future development plans

• ▪Allison DeAngelis is co-host of the weekly biotech podcast, The Readout Loud.
• ▪Johnson & Johnson plans to advance JNJ-4804 into late-stage testing, focusing on a growing subgroup of patients.
• ▪Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT.

1 source